Risk of skin cancers in thiopurines‐treated and thiopurines‐untreated patients with inflammatory bowel disease: A systematic review and meta‐analysis

Huang, Shaozhuo; Liu, Zhicheng; Liao, Weitang; Wei, Junxiao; Huang, Xiaowen; Yang, Chen; Xia, Yuhan; Lü, Li; Ye, Chao; Dai, Shixue

doi:10.1111/jgh.14533

Cited by 39 publications

(38 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This epidemiological shift occurring with newly industrialized and urbanized countries reflecting the experience reported in the west more than 50 years ago (2). IBD including CD and UC is associated with increased risk of intestinal and extraintestinal cancers (6)(7)(8)(9)(10)(11). Local and systemic inflammation were postulated to contribute to the increased risk of cancer in IBD patients (31).…”

Section: Discussionmentioning

confidence: 97%

“…In the latter half of the 20th century, IBD was traditionally considered as a disease of westernized nations (including the USA, Canada, Australia, New Zealand, and all countries in western Europe), due to the significantly increased incidence of UC and CD in the western world (2-4) However, recent studies indicate that IBD has become a global condition with the development of newly industrialized countries whose societies have become more westernized (including South America, eastern Europe, Asia, and Africa) (2,5). IBD has been demonstrated with an increased risk of intestinal and extra-intestinal tumors (6)(7)(8)(9)(10)(11). Although recent studies (10,11) showed that IBD patients were at increased risk of bladder cancer (BCa) and prostate cancer (PCa), limited and disparate data were available for incidence of urological malignancies in these patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Inflammatory bowel disease and risk of urinary cancers: a systematic review and pooled analysis of population-based studies

et al. 2021

View full text Add to dashboard Cite

Background: The aim of this study is to elucidate the risk of urologic cancers in patients with Crohn's disease (CD) and ulcerative colitis (UC).Methods: Electronic databases including PubMed, the Cochrane Library, Embase and Web of Science, and manual retrieval were conducted from inception to June 2020. Two reviewers independently searched the above databases and selected the studies using prespecified standardized criteria. The Newcastle-Ottawa Scale was used to assess the risk of bias in the included studies, and this meta-analysis was completed by STATA version 14.2.Results: A total of 12 cohort studies and 4 case-control studies were included in this meta-analysis. Overall, patients with inflammatory bowel disease (IBD) were at significantly increased risk of renal cancer (RCa)[standardized incidence ratio (SIR): 1.53; 95% confidence interval (CI): 1.25-1.80; I 2 =42.4%], but not at increased risk of prostate cancer (PCa), bladder cancer (BCa) and male genital cancer. In the subgroup analysis, CD patients had a significantly higher RCa risk (SIR: 1.95; 95% CI: 1.45-2.44; I 2 =39.9%). Besides, CD patients seemed to be at borderline significantly increased risks of PCa (SIR: 1.07; 95% CI: 0.93-1.20; I 2 =15.1%) and BCa (SIR:1.19; 95% CI: 0.94-1.44; I 2 =0%), and UC patients seemed to be at borderline significantly increased risks of RCa (SIR:1.31; 95% CI: 0.94-1.67; I 2 =48.0%) and PCa (SIR: 1.13; 95% CI: 0.93-1.33; I 2 =73.5%). Notably, we observed that IBD patients in Eastern countries have significantly increased PCa risk (SIR: 2.66; 95% CI: 1.52-3.81; I 2 =13.6%), especially for UC patients (SIR: 3.01; 95% CI: 1.75-4.27; I 2 =0.0%). Conclusions:Our findings indicate that IBD patients with special reference to CD patients increase the risk of RCa. Besides, IBD patients in Asian countries have significantly increased risk of PCa, especially for UC patients. Further studies are warranted to elucidate the potential mechanism of RCa associated with IBD and the differences of the risk of urinary cancers between Eastern and Western countries.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Inflammatory bowel disease and risk of urinary cancers: a systematic review and pooled analysis of population-based studies

et al. 2021

View full text Add to dashboard Cite

show abstract

“…1). The most common reasons for excluding publications were out of scope (473), duplicates (20), and studies in the paediatric population (19).…”

Section: Literature Reviewmentioning

confidence: 99%

“…Although not identified in the selected publications, skin cancer and herpes zoster are side effects in the treatment of IBD and a matter of concern for patients and physicians [19,20]. Based on the focus group discussion, these attributes were added to the list.…”

Section: Focus Group Meetingmentioning

confidence: 99%

A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient Perspective

Louis

Ramos-Goñi

Cuervo

et al. 2020

Patient

View full text Add to dashboard Cite

Introduction Crohn's disease (CD) and ulcerative colitis (UC) are chronic, inflammatory bowel diseases (IBD). Each class and type of medication available for the treatment of IBD has distinct characteristics and long-term effects that a patient may consider. We present the results of qualitative research that aimed to develop a descriptive framework that outlines the most relevant disease and/or treatment attributes for IBD treatment decisions and focuses on the patient perspective. Methods This research employed a three-step approach: a literature review to identify a broad list of attributes, a focus group meeting including patients and clinicians to assess the relevance of the attributes, and two rounds of voting to name and define each attribute. The literature review was used to develop the initial list of attributes. Although the same attributes were defined for both UC and CD, the relative importance of each attribute to UC or CD was considered. The list of attributes was discussed and evaluated in the focus group meeting, which included eight patient representatives and nine gastroenterologists. Using feedback elicited from the focus group meeting, the research team developed a draft of the descriptive framework that grouped the attributes into domain subsets. All members of the focus group participated in two subsequent rounds of structured, online voting, which was used to refine the wording to name and define each attribute. Additionally, participants ranked all the attributes included in the descriptive framework to suggest which attributes were less relevant and could be omitted. Results Among 574 publications retrieved from the databases and registries, we identified 32 eligible publications, and an initial list of attributes was developed. This list was refined during the focus group meeting, resulting in a draft descriptive framework of attributes within subsets of domains. The final descriptive framework was developed based on structured rounds of online voting to further refine attribute names and definitions. In the final descriptive framework, a total of ten attributes were identified: abdominal pain, other disease-related pain, bowel urgency, fatigue, risk of cancer and serious infections within the next 10 years, risk of mild to moderate complications, aesthetic complications related to treatment, emotional status, sexual life, and social life and relationships. These attributes were distributed across three domains: efficacy, complications and risk, and health-related quality of life. Conclusions Through the identification of the ten most relevant attributes that influence patient decision making for IBD treatments, we developed a descriptive framework that should be considered by physicians when discussing IBD treatment options with their patients. The results of our qualitative research may also be helpful for the development of future IBD clinical studies and quantitative research.This article is part of the topical collection "Formative qualitative evidence for health preference and out...

show abstract

“…ere are numerous adverse events related to these drugs, such as nonmelanoma skin cancer (NMSC) [2][3][4][5], lymphoma, infections, and pancreatic and liver injury [6]. In most cases (5-15% of all patients on thiopurine therapy [6]), elevated liver enzymes (glutamate oxaloacetate transaminase (GOT) and glutamate pyruvate transaminase (GPT)) detect the presence of liver damage, although patients generally remain asymptomatic.…”

Section: Introductionmentioning

confidence: 99%

Increased Risk of Liver Cirrhosis during Azathioprine Therapy for Crohn’s Disease

Roselli

Innocenti

Lynch

et al. 2020

Case Reports in Gastrointestinal Medicine

View full text Add to dashboard Cite

Azathioprine is a cornerstone of the therapy of Crohn’s disease. Unfortunately, infections and malignancies are relatively common adverse effects related to this drug; however, cirrhosis is exceptionally reported as a side effect. We report the case of a 49-year-old male patient with ileocolonic steno-penetrating Crohn’s disease who developed hepatic cirrhosis while treated with azathioprine. After taking azathioprine for 3 years with regular follow-up, he developed pancytopenia, and liver cirrhosis was diagnosed with ultrasound, abdomen computed tomography scan, transient elastography, and liver biopsy. As all other causes of liver damage were excluded, azathioprine was believed to be the cause of liver injury and therefore was interrupted.

show abstract

Risk of skin cancers in thiopurines‐treated and thiopurines‐untreated patients with inflammatory bowel disease: A systematic review and meta‐analysis

Cited by 39 publications

References 40 publications

Inflammatory bowel disease and risk of urinary cancers: a systematic review and pooled analysis of population-based studies

Inflammatory bowel disease and risk of urinary cancers: a systematic review and pooled analysis of population-based studies

A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient Perspective

Increased Risk of Liver Cirrhosis during Azathioprine Therapy for Crohn’s Disease

Contact Info

Product

Resources

About